https://clinicaltrials.gov/ct2/show/NCT04516746
"The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age [ Time Frame: 1 year ]
A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs
≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case."
https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
"The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. "
So at the end of the day, the main question regarding the AZ/Oxford vaccine is whether a half-dose starter shot regimen, or longer time between doses can bring its efficacy more consistently up around 90%, which would make it only slightly less effective than the mRNA ones, or if it's efficacy is actually just lower.